Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
December 8, 2014
Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for … [Read More...]
November 20, 2014
Blueprint Medicines Unveils New Drug Discovery Program for Patients with RET Fusions at … [Read More...]